Key Highlights
- Arcturus Therapeutics shares closed up 22% at $13.45.
- The company reported a widened Q2 net loss of $23.8 million as collaboration Revenue declined.
- A $191.5 million cash position extends the runway through 2028.
- ARCT-810 clinical data is anticipated September 1, 2026, with a Phase 3 decision for ARCT-032 expected December 1, 2026.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares closed up 22% at $13.45 after the company reported a widened Q2 net loss of $23.8 million as collaboration revenue declined following reduced recognition from CSL Seqirus.
What Happened
Despite the wider loss, a $191.5 million cash position extends the company's runway through 2028, with anticipated September 1, 2026 ARCT-810 clinical data and a December 1, 2026 Phase 3 decision for cystic fibrosis candidate ARCT-032 serving as near-term catalysts.
Market Reaction
Shares rose as investors focused on the extended cash runway and the upcoming clinical catalysts rather than the widened quarterly net loss tied to declining collaboration revenue.
Outlook
The September 1, 2026 ARCT-810 data readout and the December 1, 2026 Phase 3 decision for ARCT-032 represent the next major disclosed milestones for Arcturus Therapeutics.
FAQs
Q: Why did Arcturus Therapeutics shares rise 22% despite a wider net loss?
A: Investors focused on the company's $191.5 million cash position extending its runway through 2028 and upcoming clinical catalysts.
Q: What caused Arcturus's collaboration revenue to decline?
A: Reduced recognition from CSL Seqirus.
Q: What upcoming catalysts are investors watching?
A: ARCT-810 clinical data expected September 1, 2026, and a Phase 3 decision for ARCT-032 expected December 1, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.